menu ☰
menu ˟

Afatinib shows promise for genetically mutated urothelial cancer

14 Jun 2016
The oral tyrosine kinase inhibitor afatinib exhibited significant activity in patients with metastatic, platinum-refractory urothelial cancer who harbor HER-2 or ERBB3 alterations, according to the results of a phase 2 study.“Compared to other drug...

Click here to view the full article which appeared in Hematology Oncology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.